Cullinan Therapeutics to host investor event for REZILIENT3 Phase 3 data
Cullinan Therapeutics says it will host a virtual analyst and investor event at 8:00 a.m. ETC today to feature Zipalertinib plus chemotherapy Phase 3 REZILIENT3 data presented at the IASLC 2026 World Conference on Lung Cancer.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.